US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arin Tactical Tail Risk ETF

89.97

0.0000

Volume:- -

Turnover:- -

Market Cap:54.80M

PE:- -

High:89.97

Open:89.97

Low:89.97

Close:89.97

52wk High:89.97

52wk Low:89.93

Shares:609.15K

Float Shares:609.10K

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

1 Stock Up by 63% This Year That Could Double, According to Wall Street

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ATTR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATTR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATTR\",,,,,undefined,":{"symbol":"ATTR","market":"US","secType":"STK","nameCN":"Arin Tactical Tail Risk ETF","latestPrice":89.965,"timestamp":1761940800000,"preClose":89.965,"halted":0,"volume":0,"delay":0,"floatShares":609100,"shares":609146,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"10-31 16:00:00 EDT","open":89.965,"high":89.965,"low":89.965,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1762160400000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":89.965,"sharesOutstanding":609146,"nav":89.98,"aum":54810957.08,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATTR\",,,,,undefined,":{"symbol":"ATTR","floatShares":609100,"roa":"--","roe":"--","lyrEps":0,"shares":609146,"dividePrice":0,"high":89.965,"amplitude":0,"preClose":89.965,"low":89.965,"week52Low":89.93,"pbRate":"--","week52High":89.97,"institutionHeld":0,"latestPrice":89.965,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":89.965,"prevYearClose":89.97,"prevWeekClose":89.97,"prevMonthClose":89.965,"prevQuarterClose":89.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATTR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATTR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATTR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATTR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2578648062","title":"Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)","url":"https://stock-news.laohu8.com/highlight/detail?id=2578648062","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578648062?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:30","pubTimestamp":1761564600,"startTime":"0","endTime":"0","summary":"Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct.  27, 2025  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174462/0/en/Intellia-Therapeutics-Provides-Update-on-MAGNITUDE-Clinical-Trials-of-Nexiguran-Ziclumeran-nex-z.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ODD","BK4556","LU1861559042.SGD","LU1861558580.USD","BK4139","BK4588","BK4535","NTLA","BK4183","BK4611","IE0009354923.USD","ATTR","CRSP"],"gpt_icon":0},{"id":"2573924963","title":"1 Stock Up by 63% This Year That Could Double, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2573924963","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573924963?lang=en_us&edition=fundamental","pubTime":"2025-10-07 21:45","pubTimestamp":1759844700,"startTime":"0","endTime":"0","summary":"Some math suggests that even Wall Street is lowballing the stock's potential.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F835831%2Fscientist-altering-dna-genome-project.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F835831%2Fscientist-altering-dna-genome-project.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/07/1-stock-up-by-63-this-year-that-could-double/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/07/1-stock-up-by-63-this-year-that-could-double/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0106261612.USD","LU0012050646.USD","IE00B19Z6F94.USD","IE0034390439.USD","LU1169590202.USD","LU0205193047.USD","IE00B64QTZ34.USD","LU0205194284.USD","HAE","BK4198","IE00BLDYK493.USD","LU1169589451.USD","ATTR"],"gpt_icon":0},{"id":"2570557828","title":"Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM","url":"https://stock-news.laohu8.com/highlight/detail?id=2570557828","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570557828?lang=en_us&edition=fundamental","pubTime":"2025-09-28 23:15","pubTimestamp":1759072500,"startTime":"0","endTime":"0","summary":"- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the  cumulative risk of CVM or recurrent CVH through Month 30 ver","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/28/3157362/0/en/Acoramidis-Begins-to-Reduce-Cumulative-Cardiovascular-Outcomes-Within-the-First-Month-of-Treatment-in-Patients-with-ATTR-CM.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","CM","CVM","BK4505","BK4516","LU0689626769.HKD","BK4139","BK4129","LU2308191902.HKD","CSII","BK4207","ASM","ACM","BK4588","BK4188","ATTR","LU0124676726.USD","BK4585","BBIO"],"gpt_icon":0},{"id":"2570301564","title":"Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2570301564","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570301564?lang=en_us&edition=fundamental","pubTime":"2025-09-25 21:52","pubTimestamp":1758808320,"startTime":"0","endTime":"0","summary":"One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or improvement in disease-related clinica","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/25/3156402/0/en/Intellia-Therapeutics-Announces-Positive-Longer-Term-Phase-1-Data-for-Nexiguran-Ziclumeran-nex-z-in-Patients-with-Hereditary-Transthyretin-ATTR-Amyloidosis-with-Polyneuropathy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1861559042.SGD","BK4556","BK4535","NTLA","CRSP","LU1861558580.USD","ATTR","BK4139","BK4585","BK4611"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ATTR\",params:#limit:6,delay:false,,,undefined,":[]}}